1 / 18

Hypersensitivity Reactions (HSRs)

Hypersensitivity Reactions (HSRs). Objectives. The learner will be able to: Know the signs and symptoms hypersensitivity reactions (HSRs). Verbalize the proper emergency management of a suspected HSR. Problem and Incidence. Cancer therapies have the potential to cause HSRs.

egil
Download Presentation

Hypersensitivity Reactions (HSRs)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hypersensitivity Reactions(HSRs)

  2. Objectives The learner will be able to: • Know the signs and symptoms hypersensitivity reactions (HSRs). • Verbalize the proper emergency management of a suspected HSR.

  3. Problem and Incidence • Cancer therapies have the potential to cause HSRs. • These reactions may be triggered by the therapeutic agent, the diluent, or the solution. • The general incidence of HSRs is 5%, but the incidence for some agents is much higher.

  4. Hypersensitivity Reactions • Reactions are either anaphylactic or anaphylactoid. • Anaphylactic reactions to chemotherapy agents are allergic reactions mediated by the release of Ig-E from the immune system. • Anaphylactoid reactions are not mediated by Ig-E and caused by the release of cytokines.

  5. Hypersensitivity Reactions • There are various types of HSRs; some are localized and mild, others are generalized and moderate to severe, and still others are life-threatening.

  6. Immune System Function in Anaphylactic Reactions • An antigen is recognized as foreign. • The body forms antibodies as part of an adaptive immune response. • The most common antibody or immunoglobulin formed during an allergic reaction is Ig-E. • Ig-E promotes histamine release from mast cells and basophils.

  7. Hypersensitivity and Anaphylaxis • HSRs are more likely to occur with the second dose of an agent but can occur with the first. • Symptoms can range from itching at the injection site to systemic shock. • The response usually occurs within 5-10 minutes of the initiation of therapy. Quicker onset of symptoms increases the severity of the reaction. • Delayed reactions can occur 10-12 hours after administration.

  8. Immune System Function in Anaphylactoid Reactions • Immune response to a foreign antigen (drug or substance) causes T lymphocytes actions to result in the release cytokines.

  9. Immune System Function in Anaphylactoid Reactions • Cytokines are proteins that help coordinate immune and inflammatory responses. • Cytokines that mediate inflammatory responses include interleukines, interferons, and tumor necrosis factors. • Cytokine release can cause fever, chills, headache, nausea, fatigue, and hypertension.

  10. Hypersensitivity Reactions • Although anaphylactic and anaphylactoid reactions differ in their origin, the clinical symptoms can be the same for both reactions. • Therefore, the management is the same for both types.

  11. Risk Factors for All Hypersensitivity Reactions • Chemotherapy and biotherapy are known to cause hypersensitivity. • High doses of high risk agents • IV administration of high risk agents • Agents derived from bacteria and L-asparaginase • Crude preparations of agents, such as phase 1 studies

  12. Risk Factors for All Hypersensitivity Reactions • Preexisting allergies, especially to food, drugs, bee stings, blood products, and contrast dye • Previous exposure to the agent • Carboplatin reaction risk increases at the sixth infusion and peaks at the eighth infusion • Oxalipatin reactions occur more frequently after five cycles • Failure to administer pre-meds

  13. Preadministration Guideline • Obtain and record baseline vital signs. • Review allergy history. • Administer pre-medications. • Antipyretic • Histamine blocker (H1 and H2) • Corticosteroid • Ensure emergency meds are available, and preferable to have an order to use prior to treatment. • Instruct patient on signs and symptoms to report. • Perform scratch test or intradermal skin test if recommended.

  14. Clinical Manifestations • Uneasiness or agitation • Tightness in the chest • Shortness of breath with or without wheezing • Hypotension • Tachycardia • Headache • Urticaria or rash • Localized or generalized itching • Periorbital or facial edema • Lightheadedness or dizziness • Abdominal cramping, diarrhea, nausea, or vomiting

  15. Emergency Management • Stop infusion • Maintain an IV line with saline • Stay with patient; call for help • Place patient in supine position—legs elevated if hypotensive • Monitor vital signs • Maintain an airway • Administer or order emergency medications • Diphenhydramine, Famotidine, Corticosteroids, Epinephrine • Provide emotional support • Document treatment and responses • Remember that symptoms may reoccur

  16. Managing Reactions Caused by Cytokine Release • Most of these reactions are caused by monoclonal antibodies. • Unlike anaphylaxis, cytokine release reactions often can be managed by short-term cessation of the infusion and administration of histamine blockers, and restarting the infusion at a slower rate.

  17. Patient and Family Teaching • Prior to administration of agents, teach patients that HSRs are a possibility. • Instruct patients about what symptoms to report. • After therapy, talk to patients about risk for delayed or recurrent reaction.

  18. References Povolich, M., Whitford, J.M., & Olsen, M. (Eds.). (2009). Chemotherapy and biotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society. Viale, P.H. (2010). Dermatologic complications. In J. Eggert (Ed.), Cancer basics (pp. 378-377). Oncology Nursing Society: Pittsburgh, PA. Viale, P.H., & Sanchez-Yamamoto, D. (2010). Biphasic and delayed hypersensitivity reactions: Implications for oncology nursing. Clinical Journal of Oncology Nursing, 14(3), 347-356. Vogel, W.H. (20120). Infusion reactions: Diagnosis, assessment, and management. Clinical Journal of Oncology Nursing, 14(2), E10-E21.

More Related